McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan is quoted in an April 27, 2017 edition of FiercePharma.com in an article entitled, “As Supreme Court steps into tangled biosimilars law, IP experts weigh in.” U.S. Supreme Court justices took their shot at picking apart the knotty Biologics Price Competition and Innovation Act on Wednesday, questioning Amgen and Sandoz attorneys about the “patent dance” leading up to a biosimilar market launch. View the article